CompletedPhase 2NCT03840772
Eribulin in Advanced Solitary Fibrous Tumor
Studying Solitary fibrous tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Italian Sarcoma Group
- Principal Investigator
- Silvia Stacchiotti, MDFondazione IRCCS INT di Milano
- Intervention
- Eribulin(drug)
- Enrollment
- 16 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2024
Study locations (3)
- Azienda Ospedaliera Universitaria Paolo Giaccone, Palermo, PA, Italy
- Policlinico Universitario Campus Biomedico, Roma, RM, Italy
- Fondazione IRCCS INT Milano, Milan, Italy
Collaborators
Eisai Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03840772 on ClinicalTrials.gov